Seladelpar

Seladelpar
Clinical data
Trade names	Livdelzi
Other names	MBX-8025; RWJ-800025
AHFS/Drugs.com	Livdelzi
License data	US DailyMed: Seladelpar;
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid;
CAS Number	851528-79-5;
PubChem CID	11236126;
DrugBank	DB12390;
ChemSpider	9411171;
UNII	7C00L34NB9;
KEGG	D11256;
ChEMBL	ChEMBL230158;
CompTox Dashboard (EPA)	DTXSID001045332 ;
Chemical and physical data
Formula	C21H23F3O5S
Molar mass	444.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C;
	InChI InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1; Key:JWHYSEDOYMYMNM-QGZVFWFLSA-N;

Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis.^[1] It is used as the lysine dihydrate salt.^[1] It is a PPARδ receptor agonist.^[1]^[2]^[3] The compound was licensed from Janssen Pharmaceutica NV.^[4]

Seladelpar was approved for medical use in the United States in August 2024.^[1]^[5]

Medical uses

Seladelpar is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.^[1]

Clinically, Seladelpar reduces pruritus and IL-31 in patients with primary biliary cholangitis.^[6]

References

^ ^a ^b ^c ^d ^e ^f "Livdelzi- seladelpar lysine capsule". DailyMed. 14 August 2024. Retrieved 5 September 2024.
^ Billin AN (October 2008). "PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307. S2CID 86564263.
^ Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, et al. (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". The Journal of Clinical Endocrinology and Metabolism. 96 (9): 2889–2897. doi:10.1210/jc.2011-1061. PMID 21752880.
^ "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Metabolex, Inc. 2005. Archived from the original on 17 October 2006.
^ "Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA" (Press release). Gilead. 14 August 2024. Retrieved 15 August 2024 – via Business Wire.
^ Kremer AE, Mayo MJ, Hirschfield GM, Levy C, Bowlus CL, Jones DE, et al. (July 2024). "Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis". Hepatology. 80 (1): 27–37. doi:10.1097/HEP.0000000000000728. PMC 11191048. PMID 38117036.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

[Livdelzi_FDA_label-1] ^ ^a ^b ^c ^d ^e ^f "Livdelzi- seladelpar lysine capsule". DailyMed. 14 August 2024. Retrieved 5 September 2024.

[pmid18808307-2] Billin AN (October 2008). "PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: an adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307. S2CID 86564263.

[pmid21752880-3] Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, et al. (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". The Journal of Clinical Endocrinology and Metabolism. 96 (9): 2889–2897. doi:10.1210/jc.2011-1061. PMID 21752880.

[Metabolex2006-4] "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Metabolex, Inc. 2005. Archived from the original on 17 October 2006.

[5] "Gilead's Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA" (Press release). Gilead. 14 August 2024. Retrieved 15 August 2024 – via Business Wire.

[6] Kremer AE, Mayo MJ, Hirschfield GM, Levy C, Bowlus CL, Jones DE, et al. (July 2024). "Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis". Hepatology. 80 (1): 27–37. doi:10.1097/HEP.0000000000000728. PMC 11191048. PMID 38117036.

[1]

[2]

[3]

[4]

[5]

[6]